News Release

Science Article Cites HemogloBind™ in Reticulocyte–Red Blood Cell Transition Study

MONMOUTH JUNCTION, NJ, February 28, 2019 -- Biotech Support Group reports on a Science article describing the simplicity and efficiency of their hemoglobin depletion technology for improving LC-MS analysis from lysed reticulocytes. The citation is:  

Nguyen, Anthony T., et al. "UBE2O remodels the proteome during terminal erythroid differentiation." Science 357.6350 (2017): eaan0218.

The mechanisms that drive reticulocyte transition to red blood cell in terminally differentiating cells remain largely unclear. During reticulocyte maturation, the proteome is remodeled through the programmed elimination of most generic constituents of the cell, in parallel with abundant synthesis of hemoglobin. The study used multiplexed quantitative proteomics to identify candidate substrates of UBE2O, an E2 (ubiquitin-conjugating) enzyme, in an unbiased and global manner. Because of the overly abundant presence of Hemoglobin, selective depletion of Hemoglobin was necessary. The article states “Reticulocytes were lysed by vortexing for 5 minutes at room temperature… An additional 10 bed vol of Hemoglobind™ suspension was added to the samples, which were then vortexed for another 10 min at room temperature followed by 4 min of centrifugation at 10000 x g. The supernatants, which contain hemoglobin-depleted sample, were … processed for TMT quantification.”. The authors concluded that the ubiquitin-proteasome system is not simply amplified during erythroid maturation, but suggest instead that it is broadly reconfigured to promote remodeling of the reticulocyte proteome.

“The large amount of hemoglobin in reticulocytes presents a special challenge for LC-MS quantitative analysis. Here is another article demonstrating that HemogloBind™ can drastically reduce the interference associated with large concentrations of hemoglobin, without compromising the recovery and analysis of the underlying proteome.” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

For more information on HemogloBind™, visit:

http://www.biotechsupportgroup.com/HemogloBind-Hemoglobin-Depletion-From-Hemolyzed-p/h0145.htm

For information on all Hemoglobin Removal products: visit:

https://www.biotechsupportgroup.com/Articles.asp?ID=452

About Biotech Support Group LLC 

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com

Business Development Contact:

Matt Kuruc 732-274-2866, mkuruc@biotechsupportgroup.com